DR-093 Whole genome Sequencing to estimate TEmozolomide Associated Response IN Gliomas (STEARING)
- Algoritmes
- Behandeling op maat
- Betaaltitel
- Biomarker
- cfDNA
- DNA
- Educatie
- Geen onderdeel van een categorie
- GENAYA project
- Hartwig Medical Database
- Hartwig Medical Foundation
- Hergebruik data
- Innovatie
- IT
- Kwaliteit
- Lab proces
- Lerend zorgsysteem
- Medicijn
- Moleculaire diagnostiek
- OncoAct
- oncoanalyser
- OncoAnalyser Dx
- Onderzoek
- Participerende ziekenhuizen
- Pipeline
- Preventie
- Primaire Tumor Onbekend
- Uitbehandeld
- Verhalen patiënten
- Werken in de cloud
- Wetenschappelijke publicaties
- Whole genome sequencing
- Zeldzame kankers
DR-093 Whole genome Sequencing to estimate TEmozolomide Associated Response IN Gliomas (STEARING)
“Glioblastoma multiforme (GBM) is the most common and aggressive primary brain tumor in adults. Since 2005, standard treatment consists of …
DR-155 Towards personalized cancer therapy: identifying genomic and transcriptomic features predictive of treatment response in patients with castration resistant prostate cancer.
For prostate cancer, identifying patients at risk for developing aggressive disease is clinically challenging [1]. This project aims to discover …
DR-154 Understanding co-effect of inherited and somatic alterations in cancer
Recent studies emphasize the importance of combined effects of germline and somatic alterations in cancer. The aim of the project …
DR-152 Cancer evolutionary dynamics
Cancers change over time. Understanding how cancers change is important for determining a patient’s prognosis and to improve the effectiveness …
DR-151 Characterizing the role of structural variations in prostate cancer
While mutations affecting protein-coding regions have been examined in prostate cancer, structural variants at the genome-wide level are still poorly …
DR-150 Discovery and Characterization of Cancer Driver Mutations in Noncoding regions
Cancer genomes harbor a substantial number of mutations, but only some contribute to tumor development. These so-called driver mutations serve …
DR-149 Discovery and Characterization of Mutational Processes and Cancer Driver Mutations in Melanoma
The discovery of driver mutations and mutational processes in melanoma is complicated by high background mutation rates. With expanded melanoma …
DR-147 An exploratory study on the prognostic and predictive value of the immune infiltrate in metastastic bladder cancer and its relation with other microenvironmental factors and long non-coding RNAs.
In urothelial cancer, prognosis and responsiveness to treatments, such as chemotherapy and checkpoint inhibitors, differs substantially between patients. Although urothelial …
DR-146 Treatment with targeted therapy based on genetic profiling by whole genome sequencing in patients with solid tumours
In the past two decades, the exploration of molecular mechanisms and genetic information in cancer led to the new approaches …
DR-145 Immune and stromal gene expression signature in metastatic prostate and breast cancer
The main reason that cancer is lethal lies in its ability to spread in the body, a process called metastasis. …
DR-142 Genomic landscape of non-small cell lung cancer (NSCLC) tumors and metastases.
Despite the advancements in lung cancer treatment in the last decades, most patients diagnosed with non-small cell lung cancer (NSCLC), …
DR-141 Driver mechanisms and regional mutation rates in the non-coding cancer genome
Cancer is caused by mutations that occur over time via genetic and environmental exposures. Some mutations called drivers unlock oncogenic …
We zijn trots dat we samen met Hartwig Medical Foundation de uitgebreide DNA-test gereed hebben gemaakt voor gebruik in de standaarddiagnostiek. Bovendien levert de DNA-test belangrijke informatie op voor een lerend zorgsysteem waarin we toekomstige patiënten nog beter kunnen behandelen.